Thrombospondin-1 expression in epithelial ovarian carcinoma: Association with p53 status, tumor angiogenesis, and survival in platinum-treated patients

Gynecologic Oncology

Volumn 82, Issue 2, 2001, Pages 273-278

  Alvarez, Angeles A ^a   Axelrod, Joseph R ^b   Whitaker, Regina S ^a   Isner, Pamela D ^a   Bentley, Rex C ^a   Dodge, Richard K ^c   Rodriguez, Gustavo C ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Ovarian cancer; Thrombospondin 1

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; THROMBOSPONDIN 1;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR VASCULARIZATION;

EID: 0034902029     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6287     Document Type: Article

References (24)

1. What is the evidence that tumors are angiogenesis dependent?
2. Angiogenesis: An update
3. Tumor angiogenesis in advanced stage ovarian carcinoma
4. Angiogenesis in primary and metastatic epithelial ovarian carcinoma
5. The prognostic significance of angiogenesis in epithelial ovarian carcinoma
6. Vascular endothelial growth factor expression in early stage ovarian carcinoma
7. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats
8. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway
9. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
10. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
11. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
12. Nonparametric estimation from incomplete observations
13. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
14. Regression models and life tables
15. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression
16. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast
17. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma
18. Alterations in tumor suppressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells
19. Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA
20. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas
21. Thrombospondins I and II messenger RNA expression in lung carcinoma: Relationship with p53 alterations, angiogenic growth factors, and vascular density
22. Inhibition of fibronectin binding and fibronectin-mediated cell adhesion to collagen by a peptide from the second type I repeat of thrombospondin
23. Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo